Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis

Simple item page
dc.contributor.authorValenzuela, Fernando
dc.contributor.authorDe La Cruz, Claudia
dc.contributor.authorLecaros, Cristobal
dc.contributor.authorFernandez, Javier
dc.contributor.authorHevia, Gonzalo
dc.contributor.authorMaul, Lara Valeska
dc.contributor.authorThyssen, Jacob P.
dc.contributor.authorVera-Kellet, Cristian
dc.contributor.authorEgeberg, Alexander
dc.contributor.authorArmijo, Daniela
dc.contributor.authorPizarro, Cristian
dc.contributor.authorRiveros, Tatiana
dc.contributor.authorCorrea, Hernan
dc.contributor.authorGuglielmetti, Antonio
dc.contributor.authorDidaskalu, Johannes A.
dc.contributor.authorWu, Jashin J.
dc.contributor.authorGriffiths, Christopher E. M.
dc.contributor.authorRomiti, Ricardo
dc.contributor.authorMaul, Julia-Tatjana
dc.date.accessioned2025-01-20T20:22:35Z
dc.date.available2025-01-20T20:22:35Z
dc.date.issued2022
dc.description.abstractBackground Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America. Aim To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis. Methods This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression. Results In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 +/- 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 +/- 11.5; body surface area 14.7 +/- 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis. Conclusions We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.
dc.fuente.origenWOS
dc.identifier.doi10.1111/ced.15384
dc.identifier.eissn1365-2230
dc.identifier.issn0307-6938
dc.identifier.urihttps://doi.org/10.1111/ced.15384
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92684
dc.identifier.wosidWOS:000875468700001
dc.issue.numero12
dc.language.isoen
dc.pagina.final2241
dc.pagina.inicio2234
dc.revistaClinical and experimental dermatology
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleComorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
dc.typeartículo
dc.volumen47
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas